We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD.

Thanks to Fierce Biotech‘s Darren Incorvaia for the feature:
www.fiercebiotech.com/research/scr...

📣 #AHA25 is almost here! We’re headed to New Orleans to share the latest on our pipeline of #CRISPR genome editing & epigenetic silencing therapies for cardiometabolic disease.

Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇

When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease.

"I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds.

For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

📣 Presenting new breakthrough data from two of our core platforms 📣

We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics.

More details in our link below 👇

At Scribe, we run on teamwork and purpose – in and out of the lab.

#JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences.

If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇

What if your DNA didn’t define your health destiny?

In his TEDx Talk, our CEO @benjaminloakes.bsky.social‬ reimagines a future where anyone could walk into their doctor’s office, get treated once, and walk out healthier for life – thanks to next-generation CRISPR-based therapies.